Neuralstem announces publication of phase 1 trial results of NSI-566
Category: #health  By Paroma Bhattacharya  Date: 2019-07-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Neuralstem announces publication of phase 1 trial results of NSI-566

Subjects were provided immunosuppressive drugs for 28 days after transplantation and were observed for up to 24 months following surgery.

The biopharmaceutical company Neuralstem, Inc. has reportedly announced that it has published a manuscript in Stem Cells Translational Medicine. Apparently, it describes the outcomes of an open label phase 1 clinical study assessing the safety and feasibility of transplantation of its key stem cell asset, NSI-566, for the treatment motor deficits that occur due to ischemic stroke. 

Sources claim that the manuscript summarizes the outcomes of an open label study which was executed at BaYi Brain Hospital, Beijing, China, with Professor Xu Ruxiang. All the nine subjects in the trial had endured chronic motor deficits due to an ischemic stroke 5-24 months before the enrollment. The patients were parted into three groups taking intracerebral injections of NSI-566 cells summing up to 12, 24, or 72 million cells.

Apparently, subjects were provided immunosuppressive drugs for 28 days after transplantation and were observed for up to 24 months following surgery. The therapy was well endured at all dosages and patients showed stable growths in Fugl-Meyer Motor Scores from starting point. This apparently indicates that the procedure is safe and may have potential to offer benefit to patients enduring motor deficits from stroke.

Dr. Ken Carter, Executive Chairman, Neuralstem, reportedly stated that the company has been grateful to the partners at BaYi Brain Hospital and to the subjects who participated in the trial. Although it was a small feasibility trial, the company has been encouraged by the safety profile of the procedure, which has led it to initiate a placebo-controlled study at the same site in September 2018.

For the record, ischemic stroke is the most common type of stroke which occurs due to a hindrance within a blood vessel delivering blood to the brain. Around 15 million individuals globally suffer stroke, out of which nearly 87 percent are ischemic strokes. Post-stroke motor shortfalls include paralysis in legs and arms and can be permanent.

Source credit: https://www.neuralstem.com/news-media/press-releases/detail/264/neuralstem-announces-publication-of-results-from-phase-1



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Aino Health inks deal with 55BirchStreet to expand in German markets
Aino Health inks deal with 55BirchStreet to expand in German markets
By Paroma Bhattacharya

Reports confirm that Sweden’s Aino Health and 55BirchStreet, a Germany-based digital consulting firm, have recently signed a new partnership agreement. 55BitchStreet will sell implementation services and licenses...

Visa acquires Payworks for an integrated payment acceptance solution
Visa acquires Payworks for an integrated payment acceptance solution
By Paroma Bhattacharya

Visa, the financial services company recently announced acquisition of Payworks, the Munich-based makers of payment gateway software for the POS (point of sale). The company plans to integrate cloud-based solution of P...

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...